Relmada Therapeutics, Inc. Stock Price - RLMD

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Relmada Therapeutics, Inc. RLMD Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.02 -1.16% 1.70 1.78 1.66 1.72 1.72 16:00:06
Bid Price Ask Price Spread Spread % News
1.66 1.80 0.14 7.78% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
14 19,510 $ 1.7058 $ 33,281 32,652 0.80 - 3.418
Last Trade Time Type Quantity Stock Price Currency
14:54:30 60 $ 1.672 USD

Relmada Therapeutics, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 56.70M 33.35M $ -8.96M - -6.33 9.54M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
261.48k $ - 0.00% - -

more financials information »

Relmada Therapeutics, Inc. News

Latest RLMD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RLMD Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week1.81.951.651.811222k-0.1-5.56%
1 Month2.482.481.651.894540k-0.78-31.45%
3 Months1.853.4181.652.174733k-0.15-8.11%
6 Months1.363.4181.151.917027k0.3425.00%
1 Year1.093.4180.81.693719k0.6155.96%
3 Years2.113.4180.611.302420k-0.41-19.43%
5 Years2.958.630.612.069929k-1.25-42.37%

Relmada Therapeutics, Inc. Description

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company focused on the development of d-methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist as new chemical entity that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. In addition, the Company has a portfolio of three 505b2 product candidates at various stages of development. These products are: LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab (oral buprenorphine, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and MepiGel (topical mepivacaine, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. These products are not currently in active development.

Your Recent History
Relmada Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.